What is the official website of NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company ?

The official website of NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company is http://www.nutrichem.de.

What is NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company's cybersecurity risk score?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company experienced?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company been affected by any supply chain cyber incidents ?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have SOC 2 Type 1 certification ?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company is not certified under SOC 2 Type 1.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have SOC 2 Type 2 certification ?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company does not hold a SOC 2 Type 2 certification.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company comply with GDPR ?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company is not listed as GDPR compliant.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have PCI DSS certification ?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company does not currently maintain PCI DSS compliance.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company comply with HIPAA ?

According to Rankiteo, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company is not compliant with HIPAA regulations.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have ISO 27001 certification ?

According to Rankiteo,NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company operate in ?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have ?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company employs approximately 73 people worldwide.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company own any subsidiaries ?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company presently has no subsidiaries across any sectors.

How many LinkedIn followers does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have ?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company's official LinkedIn profile has approximately 2,193 followers.

What is the NAICS classification code for NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company ?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have a Crunchbase profile ?

No, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company does not have a profile on Crunchbase.

Does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have a LinkedIn profile ?

Yes, NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/nutrichem-de.

How many cybersecurity incidents has NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company experienced ?

As of June 15, 2026, Rankiteo reports that NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company has not experienced any cybersecurity incidents.

How many peer or competitor companies does NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company have ?

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company has an estimated 5,691 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

NDPGBBC

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company Vendor Cyber Rating & Cyber Score

nutrichem.de

Add Your Compliance Badge

NUTRICHEM DIÄT + PHARMA GMBH and its subsidiary inkospor® are part of the B. Braun Group of companies. NUTRICHEM DIÄT + PHARMA GMBH develops, manufactures, and packages high-quality nutritional and pharmaceutical products with state-of-the-art technology for clients across the globe. Backed by a powerhouse R&D department, we help our clients manufacture nutritional products in the areas of: -Enteral Nutrition -OEM -Sports Nutrition NUTRICHEM had its early roots in the raw materials industry in 1977 and over the years has developed into a major food manufacturer in Germany that has penetrated beyond clinical nutrition into the world of sports nutrition. Over the years, NUTRICHEM was taken over by B. Braun Melsungen AG in order to

NDPGBBC A.I CyberSecurity Scoring

Scoring History

NDPGBBC

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

NDPGBBC Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for NDPGBBC

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company in 2026.

Incident Types NDPGBBC vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company in 2026.

Incident History - NDPGBBC (X = Date, Y = Severity)

Loading…

SUBSIDIARY

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company Subsidiaries

NDPGBBC

Pharmaceutical Manufacturing

Website: http://www.nutrichem.de

Company Size: 201-500 employees

B. Braun GroupMedical Equipment Manufacturing

B. Braun Medical Inc. (US)Medical Equipment Manufacturing

B. Braun New VenturesMedical Equipment Manufacturing

B. Braun Vet CareTierärztliche Leistungen

Aesculap AcademyEducation

Loading…

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company Similar Companies

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Loading…

NEWS

NUTRICHEM DIÄT + PHARMA GMBH - a B. Braun Company CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-12191

SUMMARY

A vulnerability was found in Comma AI Openpilot 0.11. This issue affects the function pickle.load/pickle.loads of the file selfdrive/modeld/modeld.py of the component Pickle Module. The manipulation results in deserialization. The attack is only possible with local access. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 7.8)

cvss2

Base Score: 6.8

Complexity: LOW

AV:L/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-12190

SUMMARY

A vulnerability has been found in Genspark AI Workspace App 2.8.4 on Android. This vulnerability affects unknown code of the component ai.mainfunc.genspark. The manipulation leads to improper authorization in handler for custom url scheme. The attack can only be performed from a local environment. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 4.3

Complexity: LOW

AV:L/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 4.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.8

REFERENCES

CVE-2026-12189

SUMMARY

A flaw has been found in Moovit Bus & Public Transit App 1.18 on Android. This affects an unknown part of the component com.tranzmate. Executing a manipulation can lead to improper authorization in handler for custom url scheme. The attack can only be executed locally. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 4.3

Complexity: LOW

AV:L/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 1.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.8

REFERENCES

CVE-2026-12188

SUMMARY

A vulnerability was detected in Grit42 Grit up to 0.11.0. Affected by this issue is some unknown functionality of the file modules/core/backend/app/controllers/concerns/grit/core/grit_entity_controller.rb of the component GritEntityController. Performing a manipulation results in sql injection. The attack may be initiated remotely. The exploit is now public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-12187

SUMMARY

A security vulnerability has been detected in GL.iNet GL-MT3000 up to 4.4.5. Affected by this vulnerability is an unknown functionality of the file /usr/bin/one_click_upgrade of the component Online Firmware Upgrade Handler. Such manipulation leads to command injection. The attack can be launched remotely. The exploit has been disclosed publicly and may be used. Upgrading to version 4.7 addresses this issue. Upgrading the affected component is advised. The vendor was contacted early, responded in a very professional manner and quickly released a fixed version of the affected product.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 8.8)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 7.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…